Calcified Tissue International

, Volume 102, Issue 5, pp 501–502 | Cite as

Osteoimmunology

Editorial

Interactions between the immune system and bone were initially recognised more than 35 years ago with the discovery by Horton that activated peripheral blood leukocytes release a soluble activity that stimulates osteoclastic bone resorption [1]. With advances in cell and molecular biology, several molecules have since been discovered that play roles both in the regulation of bone remodelling and immune responses, most notably receptor activator of nuclear factor kappa B (RANK) and RANK Ligand (RANKL) which were initially identified as mediators of T-cell activation and dendritic cell function [2] but which then were found to be crucial regulators of osteoclastogenesis [3].

The term “osteoimmunology” was first coined about 18 years ago by Arron and Choi [4] to describe the process whereby bone cells and immune cells interact when commenting on a seminal paper by Takayanagi which showed that RANKL-induced activation of osteoclasts by T-cells was counterbalanced by interferon gamma produced by the same cells [5]. Since these beginnings, interest in the discipline of osteoimmunology has evolved rapidly (Fig. 1). It is for this reason that we have devoted the current issue of Calcified Tissue International to the topic of osteoimmunology.

Fig. 1

The rise of osteoimmunology

The issue begins with an authoritative and beautifully illustrated overview of the field by Terashima and Takayanagi [6]. This review, from one of the leading laboratories in the field, details the signalling pathways used by RANKL to regulate osteoclastogenesis and considers the role of the RANK–RANKL pathway as a mediator of both systemic bone loss and the local bone loss that accompanies T-cell activation in rheumatoid arthritis. The authors then go on to discuss the importance of immune cells in fracture healing and the contribution of bone cells to the development and maturation of hematopoietic stem cells. Finally, the many paracrine factors that regulate cell–cell communication in the bone marrow are discussed. The second article by Hsu and Pacifici [7] provides a state-of-the-art review on the related disciplines of osteoimmunology and osteomicrobiology which links nicely with the recent special issue of Calcified Tissue International which focussed on the relation between the microbiota and bone health [8]. The osteoimmunology special issue continues with an article by Hauser and Harre who review the role that autoantibodies play in regulating bone metabolism through their interactions with Fc receptors and effects on the RANK–RANKL–OPG system [9].

The next series of articles deal with the abnormalities of bone metabolism that occur in different rheumatic diseases. Shim et al. discuss the cytokines and signalling pathways implicated in the pathogenesis rheumatoid arthritis, the mechanisms of bone erosions and current therapeutic approaches as well as discussing future prospects for repairing erosive damage [10]. The next article by Van Mechelen et al. [11] reviews the pathophysiology of ankylosing spondylitis with particular emphasis on the molecular mechanisms responsible for the florid skeletal abnormalities that are characteristic of this disease. Paine and Ritchlin [12] review the alterations in bone remodelling that occur in psoriatic arthritis. In a comprehensive article, the authors discuss the mediators of abnormal bone resorption and formation; the role of environmental factors such as trauma, the intestinal microbiome, obesity and smoking; and the effects of currently available treatments on radiographic progression. The disease-specific section concludes with a review by Bultink [13] who discusses recent advances in understanding the mechanisms of bone loss in systemic lupus erythematosus and other connective tissue diseases as well as giving details of the clinical features, epidemiology and treatment of osteoporosis in these conditions.

The special issue closes with two articles which evaluate the effects of anti-rheumatic drug treatments on the skeleton. The review by Guler-Yuksel et al. deals with the effects of glucocorticoids on bone [14]. The authors draw attention to the fact that while glucocorticoids may have negative effects on the skeleton, bone sparing effects can also be observed in the context of inflammatory diseases as the result of their anti-inflammatory and immunosuppressive properties. These and other aspects of glucocorticoid use are reviewed along with recent developments and the latest guidance on management of glucocorticoid induced osteoporosis by pharmacological and non-pharmacological means. The final article by Dubrovsky et al. [15] deals with the effects of anti-rheumatic drugs on the skeleton, covering the effects of traditional disease modifying anti-rheumatic drugs as well as biological therapies. The article also reviews current knowledge with regard to the effects of anti-osteoporosis medications in patients with rheumatic disease.

It has been our great pleasure in working with this talented group of authors to bring this special issue together for our readers. We hope that you will enjoy reading the articles as much as we have.

Notes

Compliance with Ethical Standards

Conflict of interest

Stuart H. Ralston and Georg Schett declare that they have no conflict of interest.

References

  1. 1.
    Horton JE, Raisz LG, Simmons HA, Oppenheim JJ, Mergenhagen SE (1972) Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177:793–795CrossRefPubMedGoogle Scholar
  2. 2.
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179CrossRefPubMedGoogle Scholar
  3. 3.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveria-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323CrossRefPubMedGoogle Scholar
  4. 4.
    Arron JR, Choi Y (2000) Bone versus immune system. Nature 408:535–536CrossRefPubMedGoogle Scholar
  5. 5.
    Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross- talk between RANKL and IFN-gamma. Nature 408:600–605CrossRefPubMedGoogle Scholar
  6. 6.
    Terashima A, Takayanagi H (2018) Overview of osteoimmunology. Calcif Tissue Int.  https://doi.org/10.1007/s00223-018-0417-1 PubMedGoogle Scholar
  7. 7.
    Hsu E, Pacifici R (2017) From osteoimmunology to osteomicrobiology: how the microbiota and the immune system regulate bone. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0321-0 PubMedGoogle Scholar
  8. 8.
    Rizzoli R (2018) Microbiota and bone health: the gut-musculoskeletal axis. Calcif Tissue Int 102:385–386CrossRefPubMedGoogle Scholar
  9. 9.
    Hauser B, Harre U (2017) The role of autoantibodies in bone metabolism and bone loss. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0370-4 PubMedCentralGoogle Scholar
  10. 10.
    Shim JH, Stavre Z, Gravallese EM (2017) Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0373-1 PubMedGoogle Scholar
  11. 11.
    Van Mechelen M, Gulino GR, de Vlam K, Lories R (2017) Bone disease in axial spondyloarthritis. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0356-2 PubMedGoogle Scholar
  12. 12.
    Paine A, Ritchlin C (2018) Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0380-2 PubMedGoogle Scholar
  13. 13.
    Bultink IEM (2017) Bone disease in connective tissue disease/systemic lupus erythematosus. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0322-z PubMedCentralGoogle Scholar
  14. 14.
    Guler-Yuksel M, Hoes JN, Bultink IEM, Lems WF (2018) Glucocorticoids, inflammation and bone. Calcif Tissue Int.  https://doi.org/10.1007/s00223-017-0335-7 PubMedGoogle Scholar
  15. 15.
    Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton. Calcif Tissue Int.  https://doi.org/10.1007/s00223-018-0401-9 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular MedicineUniversity of Edinburgh, Western General HospitalEdinburghUK
  2. 2.Department of Internal Medicine 3, Rheumatology and ImmunologyFriedrich Alexander University Erlangen-Nuremberg and Universitatsklinikum ErlangenErlangenGermany

Personalised recommendations